Sandoz (SIX:SDZ / OTCQX:SDZNY), the global leader in affordable medicines, will host its 2026 capital markets day for investors and analysts on Tuesday, 8 September, at the London Stock Exchange. The event, themed 'Maximising Sandoz Value in Its Golden Decade for Biosimilars,' will run from 13:30 to 17:00 UK time and be available via live webcast. In-person attendance is by invitation only on a first-come, first-served basis.
The formal part of the event will begin at 13:30 and is expected to outline Sandoz's strategic priorities, particularly in biosimilars, which the company identifies as a key growth driver over the next decade. Sandoz, which celebrates 20 years of pioneering biosimilars in 2026, aims to leverage its experience and pipeline to capture market opportunities. Details of how to access the live webcast are available here.
In addition to the capital markets day, Sandoz plans to host an investor and analyst site visit in Slovenia from 9-10 November. The visit will provide further insight into the company's new biosimilars development and supply-chain hub. Attendance will also be by invitation only, and the event will not be webcasted.
The announcement comes as Sandoz reports net sales of USD 11.1 billion in 2025, driven by its portfolio of approximately 1,300 medicines. With a heritage dating back to 1886 and a workforce of over 20,000 colleagues representing 100 nationalities, Sandoz reaches over one billion patients globally. The company's focus on affordable medicines and biosimilars positions it to generate substantial healthcare savings and social impact.
Forward-looking statements in the release caution that actual outcomes may vary materially due to risks such as global economic conditions, exchange rates, legal provisions, and competitive activities. Sandoz undertakes no obligation to update these statements except as required by law.
